Major Breakthrough: Daily Pill Doubles Survival for Pancreatic Cancer
BBC Health
Discover how daraxonrasib, a new pill, is nearly doubling survival rates for pancreatic cancer patients, offering hope in a challenging battle against this deadly disease.
Daraxonrasib nearly doubles pancreatic cancer survival rates!
Patients on daraxonrasib live an average of 13.2 months.
Only 43.6% of daraxonrasib patients face severe side effects.
Experts call this a game changer for pancreatic cancer treatment.